Key Takeaway: Cardiff Oncology has reported positive results from its Phase 2 CRDF-004 trial, which were presented at the ASCO conference. The data supports the advancement of onvansertib in combination with FOLFIRI/bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC). Following a successful End-of-Phase 2 meeting with the FDA, the company is aligned on key program elements.
Market Sentiment Analysis
POSITIVE FACTORS
Positive Phase 2 data for CRDF-004 presented at ASCO.
Advancement of onvansertib into registrational program.
Successful End-of-Phase 2 meeting with FDA.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+51%
120-day peak, hindsight
Typical move
22.5%
average across 2 past catalysts
Cash runway
~12 mo
Medium dilution risk
Lead asset
Onvansertib
Phase 2 · Small-cell Lung Cancer
Full Press Release Details
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following successful End-of-Phase 2 meeting with FDA, Company aligned on key elements of
Frequently Asked Questions
What were the results of the Phase 2 CRDF-004 trial?
The Phase 2 CRDF-004 trial showed positive data presented at ASCO.
What is onvansertib used for?
Onvansertib is being advanced for first-line treatment of RAS-mutated mCRC.
What did the FDA meeting achieve?
The End-of-Phase 2 meeting with the FDA was successful, aligning on key program elements.